A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy and safety of molidustat in non-dialysis subjects with renal anemia who are not treated with Erythropoiesis-Stimulating Agents (ESAs).

Official Title
-----------------
A Randomized, Open-label, Active-controlled, Parallel-group, Multicenter Study to Investigate the Efficacy and Safety of Oral Molidustat in Comparison to Darbepoetin Alfa in Non-dialysis Subjects With Renal Anemia Who Are Not Treated With Erythropoiesis-Stimulating Agents (ESAs)

Conditions
-----------------
Anemia, Renal Insufficiency, Chronic

Intervention / Treatment
-----------------
* Drug: Molidustat (BAY85-3934)
* Drug: Darbepoetin alfa


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects with estimated glomerular filtration rate (eGFR)< 60 mL/min/1.73m^2 (Chronic kidney disease [CKD] stages 3 to 5) Body weight > 40 and ≤ 160 kg at screening Male or female subject ≥ 20 years of age at screening Not on dialysis and not expected to start dialysis during the study period Not treated with ESAs and/or HIF-PH inhibitors within 8 weeks prior to randomization Mean of the last 2 central laboratory Hb levels during the screening period must be ≥ 8.0 and < 11.0 g/dL (2 measurements must be taken ≥ 2 days apart and the difference between the 2 measurements must be < 1.2 g/dL) and the last measurements must be taken within 14 days prior to randomization Ferritin ≥ 50 ng/mL at screening Exclusion Criteria: New York Heart Association (NYHA) Class III or IV congestive heart failure History of cardio- (cerebro-) vascular events (e.g., unstable angina, myocardial infarction, stroke, pulmonary thromboembolism, and acute limb ischemia) within 6 months prior to randomization Sustained and poorly controlled arterial hypertension (defined as systolic BP≥ 180mmHg or diastolic BP ≥ 110mmHg) or hypotension (defined as systolic BP < 90mmHg) at randomization Proliferative choroidal or retinal disease, such as neovascular age-related macular degeneration or proliferative diabetic retinopathy requiring invasive treatment (e.g., intraocular injections or laser photocoagulation)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Molidustat (BAY85-3934)<br>Molidustat group | Drug: Molidustat (BAY85-3934)<br>* Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response<br>|
| Active Comparator: Darbepoetin alfa<br>Darbepoetin alfa group | Drug: Darbepoetin alfa<br>* Starting dose of darbepoetin alfa once every 2 weeks will be titrated based on the subject's Hb (Hemoglobin) response<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean Hb (Hemoglobin) level |  | From week 30 to 36 | 
| Change in hemoglobin level from baseline to the average during the evaluation period |  | Baseline and week 30 to 36 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Responder rate: proportion of responders among the subjects | Responder is defined as meeting all of the following criteria: (i) Mean of the Hb levels in the target range (ii) ≥ 50% of the Hb levels in the target range (iii) No rescue treatment | From week 30 to 36 | 
| Rate of rise in Hb (Hemoglobin) level (g/dL/week) |  | Up to 8 weeks | 
| Rate of rise in Hb (Hemoglobin) level (g/dL/week) |  | Up to 4 weeks | 
| Proportion of subjects who meet each component of the response | Response: (i) Mean of the Hb levels in the target range (ii) ≥ 50% of the Hb levels in the target range (iii) No rescue treatment | From week 30 to 36 | 
| Cumulative proportion of subjects who achieve the lower limit of the target Hb range at least once |  | Up to 52 weeks | 
| Change in Hb level |  | Baseline and up to 52 weeks | 
| Hb level |  | Baseline and up to 52 weeks | 
| Proportion of subjects whose mean hemoglobin level is in the target range |  | From week 30 to 36 | 
| Proportion of subjects whose mean hemoglobin level is above the target range |  | From week 30 to 36 | 
| Proportion of subjects whose mean hemoglobin level is below the target range |  | From week 30 to 36 | 
| Proportion of subjects with hemoglobin levels in the target range |  | Up to 52 weeks | 
| Proportion of subjects with hemoglobin levels above the target range |  | Up to 52 weeks | 
| Proportion of subjects with hemoglobin levels below the target range |  | Up to 52 weeks | 
| Proportion of subjects whose maximum rise in Hb between each consecutive visits is above 0.5 g/dL/week | Defined as change in Hb level / duration between two visits (weeks) | Up to 52 weeks | 
| Number of participants with serious adverse events |  | Up to 52 weeks | 
| Maximum concentration (Cmax) |  | At baseline, week 12, week 24 and week 52 | 
| Area under the concentration-time curve (AUC) |  | At baseline, week 12, week 24 and week 52 | 
| EPO (Erythropoietin) serum concentration |  | At baseline, week 12, week 24 and week 52 |